LabGenomics Co., Ltd.

As of March 31, 2026, LabGenomics Co., Ltd. carries a market capitalization of 478.85B, placing it among publicly traded companies globally. Its enterprise value stands at 486.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

LabGenomics Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, LabGenomics Co., Ltd. has 74.24M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 4.55, and the price-to-book ratio stands at 3.21.

These figures are as of March 31, 2026. The EV/Sales ratio of 5.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 486.44B versus a market cap of 478.85B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, LabGenomics Co., Ltd. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.21, indicating elevated leverage, while an interest coverage ratio of -7.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, LabGenomics Co., Ltd. posted a negative return on equity (ROE) of -35.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.33, reflecting losses generated across the asset base. The company generates approximately 474.31M in revenue per employee across its workforce of 177.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.07 indicates how many times LabGenomics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, LabGenomics Co., Ltd. recorded 4.81B in income tax expense. The company reported a pretax loss of -58.90B and -63.71B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, LabGenomics Co., Ltd.'s stock has declined approximately 84.99% over the past 52 weeks. The 50-day moving average sits at 2,966.10, while the 200-day moving average is 6,032.73.

Over the twelve months ended March 31, 2026, LabGenomics Co., Ltd. generated 84.19B in revenue and converted that into -63.71B in net income, yielding earnings per share of -1,072.66. EBITDA reached -42.66B, while operating income came in at -51.98B.

As of March 31, 2026, LabGenomics Co., Ltd. holds 53.87B in cash and equivalents against 61.47B in total debt, resulting in a net debt position of 49.98B. Total book value stands at 149.16B, with working capital of 10.43B providing operational flexibility.

LabGenomics Co., Ltd. produced -28.49B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.79B in capital expenditures, free cash flow totaled -30.29B - equivalent to -509.97 per share.

Over the twelve months ended March 31, 2026, LabGenomics Co., Ltd. posted a gross margin of 34.33, reflecting its pricing power and cost economics. The operating margin of -61.74 and net profit margin of -75.67 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -7.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.46, meaning LabGenomics Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

LabGenomics Co., Ltd.'s most recent stock split took place on September 23, 2026 with a 5:1 split ratio.

As of March 31, 2026, LabGenomics Co., Ltd. has an Altman Z-Score of 3.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.